FDA Expands ANKTIVA Approval to Include Papillary-Only NMIBC
ImmunityBio said the FDA expanded ANKTIVA’s indication to include BCG-unresponsive non-muscle invasive bladder cancer patients with papillary-only tumors.
Key Highlights:Original SEC Filing: ImmunityBio, Inc. [ IBRX ] - 8-K - Oct. 14, 2026This is an AI-powered summary. It may contain inaccu…